A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: Dependence on CD28 signaling and preferential inhibition of IL-10 production

被引:65
作者
Koprak, S [1 ]
Staruch, MJ [1 ]
Dumont, FJ [1 ]
机构
[1] Merck & Co Inc, Merck Sharp & Dohme Res Labs, Dept Immunol, Rahway, NJ 07065 USA
关键词
D O I
10.1006/cimm.1998.1448
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cytokine production upon T cell activation results from the integration of multiple signaling pathways from TCR/CD3 and from costimulatory molecules such as CD28. Among these pathways, the possible role of p38 mitogen activated protein kinase (MAPK) is the least understood. Here, we used a highly specific p38 MAPK inhibitor, the SB203580 compound, to examine the role of this enzyme in the induction of various cytokines in human T cells stimulated with anti-CD3 and anti-CD28 mAb together or in combination with PMA. Cytokine induction was monitored by ELISA and at the mRNA level. While SB203580 had little effect on IL-2 production and proliferation, it significantly reduced the production of several other cytokines, The secretion of IL-4, IL-5, IL-13, and TNF-alpha was inhibited by 20-50% with modes of T cell activation involving the CD28 pathway, whereas their mRNA expression was little affected. In contrast, IFN-gamma induction via CD28/PMA or CD3/CD28, but not CD3/PMA, was markedly diminished both at the protein and at the mRNA levels, Most interestingly, SB203580 also sup pressed IL-10 secretion and mRNA induction via CD28-dependent activation by 75-85% (IC50 similar to 0.2 mu M). Subset analysis suggested that this inhibition did not reflect a differential effect on T cell subsets. Therefore, p38 MAPK activity appears to contribute to cytokine production, mostly via CD28-dependent signaling, Moreover, IL-10 seems to rely more on this activity than other cytokines for its induction in T cells. (C) 1999 Academic Press.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 42 条
  • [1] Differential signaling by lymphocyte antigen receptors
    AlberolaIla, J
    Takaki, S
    Kerner, JD
    Perlmutter, RM
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 125 - 154
  • [2] The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumour necrosis factor
    Beyaert, R
    Cuenda, A
    VandenBerghe, W
    Plaisance, S
    Lee, JC
    Haegeman, G
    Cohen, P
    Fiers, W
    [J]. EMBO JOURNAL, 1996, 15 (08) : 1914 - 1923
  • [3] The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation
    Chu, YF
    Solski, PA
    KhosraviFar, R
    Der, CJ
    Kelly, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) : 6497 - 6501
  • [4] The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs)
    Clerk, A
    Sugden, PH
    [J]. FEBS LETTERS, 1998, 426 (01) : 93 - 96
  • [6] Cohen SBA, 1997, J IMMUNOL, V158, P5596
  • [7] COMPARISON OF LYMPHOKINE SECRETION AND MESSENGER-RNA EXPRESSION IN THE CD45RA(+) AND CD45RO(+) SUBSETS OF HUMAN PERIPHERAL-BLOOD CD4(+) AND CD8(+) LYMPHOCYTES
    CONLON, K
    OSBORNE, J
    MORIMOTO, C
    ORTALDO, JR
    YOUNG, HA
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) : 644 - 648
  • [8] T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation
    Crawley, JB
    Rawlinson, L
    Lali, FV
    Page, TH
    Saklatvala, J
    Foxwell, BMJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) : 15023 - 15027
  • [9] SB-203580 IS A SPECIFIC INHIBITOR OF A MAP KINASE HOMOLOG WHICH IS STIMULATED BY CELLULAR STRESSES AND INTERLEUKIN-1
    CUENDA, A
    ROUSE, J
    DOZA, YN
    MEIER, R
    COHEN, P
    GALLAGHER, TF
    YOUNG, PR
    LEE, JC
    [J]. FEBS LETTERS, 1995, 364 (02) : 229 - 233
  • [10] The p38 mitogen-activated protein kinase pathway in activated and anergic Th1 cells
    DeSilva, DR
    Jones, EA
    Feeser, WS
    Manos, EJ
    Scherle, PA
    [J]. CELLULAR IMMUNOLOGY, 1997, 180 (02) : 116 - 123